Deals In Depth: May 2011
With a three-way tie, deals by Glenmark/Sanofi, Elan/Proteostasis, and Mundipharma/Allos were each valued at $50 million. Takeda expanded into Europe and emerging markets through its $14 billion buy of Nycomed, while PE firm Cinven scored big when it sold IVD investment Phadia to Thermo Fisher Scientific for $3.5 billion. Shanghai Pharma's $1.9 billion IPO on the Hong Kong Stock Exchange pushed biopharma financing in May up to $2.8 billion. Late VC financings in the device sector made up the majority of fundraising, which totaled $469 million.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.